Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD).
Christopher D. Riemann, MD, Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine, will present updated interim results from the ongoing phase 1/2a study of OpRegen at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020) during the Original Paper Session on November 15, 2020. Dr. Riemann will participate in a call to discuss the interim results on November 17, 2020 at 4:00 pm Eastern Time/1:00 pm Pacific Time. Interested parties can register for the event on the Solebury Trout Events Page and access the live webcast discussion on the Events and Presentations section of Lineage’s website.
“We are fortunate to have an esteemed surgical expert available to discuss our updated interim data from the ongoing clinical trial of OpRegen for the treatment of dry AMD,” Brian Culley, CEO, said in a company news release. “Dr. Riemann’s first-hand experience not only with OpRegen RPE cells, but also with the Orbit SDS delivery device, make him an ideal person to review data emerging from the ongoing OpRegen clinical study, which we expect to complete enrollment before year-end.”